ISRG Nasdaq Health Care Equipment Financials FY2016βFY2025
Intuitive Surgical had $10.1B of revenue in fiscal 2025, up 20.5% on the year before. Over five years, revenue changed +18.2% a year on average.
Hi! I read Intuitive Surgicalβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+20.5%
Yes. Sales grew 20.5% last year.
Does it make a profit?
28.4%
Yes. It keeps 28.4% of every sale as profit.
Does profit turn into cash?
24.8%
Yes. 24.8% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
54.7x
One share costs 54.7 times its yearly profit per share. Typical for its sector: 27.9x.
Rules of thumb on reported numbers. A starting point, not a recommendation.
About these figures. Intuitive Surgical reports no borrowings, so debt is counted as zero. Share counts and per-share figures for earlier years are restated for a stock split (3-for-1), so every year is on today's share basis.
Is it selling more, and how much does it keep?
KIRA Β· Intuitive Surgical had $10.1B of revenue in fiscal 2025, up 20.5% on the year before. Over five years, revenue changed +18.2% a year on average. Its operating margin was 29.3%, up 1.1Β pts: of every 100 in sales, about 29 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Intuitive Surgical made $2.9B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 15.9% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $2.5B in fiscal 2025, 24.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Intuitive Surgical returned $2.3B to shareholders in fiscal 2025, 92% of free cash flow. The diluted share count rose 0.2%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $61.3M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$61.3M
11 insiders
Of sales under plans
100%
$61.3M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Fredrik WidmanVP Corporate Controller | Sold plan | 1,089 | $374.44 | $0.4M | Form 4 |
| Sep 11, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 25 | $365.79 | $0.0M | Form 4 |
| Sep 10, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 23 | $347.66 | $0.0M | Form 4 |
| Sep 9, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 23 | $350.20 | $0.0M | Form 4 |
| Sep 8, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 46 | $361.23 | $0.0M | Form 4 |
| Aug 21, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 77 | $375.57 | $0.0M | Form 4 |
| Aug 20, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 77 | $396.37 | $0.0M | Form 4 |
| Aug 19, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 77 | $394.26 | $0.0M | Form 4 |
| Aug 18, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 77 | $394.00 | $0.0M | Form 4 |
| Aug 17, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 77 | $390.67 | $0.0M | Form 4 |
| Aug 11, 2026 | Amy L LaddDirector | Sold plan | 72 | $393.10 | $0.0M | Form 4 |
| Aug 11, 2026 | Gary S GuthartDirector | Sold plan | 10,000 | $400.00 | $4.0M | Form 4 |
| Aug 10, 2026 | Amy L LaddDirector | Sold plan | 400 | $379.00 | $0.2M | Form 4 |
| Aug 10, 2026 | Gary LoebEVP & Chief Legal and Complian | Sold plan | 400 | $379.00 | $0.2M | Form 4 |
| Jul 31, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 28 | $351.00 | $0.0M | Form 4 |
| Jul 30, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 28 | $346.83 | $0.0M | Form 4 |
| Jul 29, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 28 | $360.21 | $0.0M | Form 4 |
| Jul 28, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 28 | $365.58 | $0.0M | Form 4 |
| Jul 27, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 28 | $344.00 | $0.0M | Form 4 |
| Jun 12, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 25 | $414.13 | $0.0M | Form 4 |
| Jun 11, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 23 | $412.16 | $0.0M | Form 4 |
| Jun 10, 2026 | Gary LoebEVP & Chief Legal and Complian | Sold plan | 400 | $424.14 | $0.2M | Form 4 |
| Jun 10, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 23 | $424.14 | $0.0M | Form 4 |
| Jun 9, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 23 | $421.13 | $0.0M | Form 4 |
| Jun 8, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 23 | $420.12 | $0.0M | Form 4 |
| Jun 1, 2026 | Iman JeddiSVP & GM da Vinci Platforms & | Sold plan | 5,625 | $420.55 | $2.4M | Form 4 |
| May 22, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 18 | $439.80 | $0.0M | Form 4 |
| May 21, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 18 | $446.04 | $0.0M | Form 4 |
| May 20, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 18 | $440.38 | $0.0M | Form 4 |
| May 19, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 18 | $440.70 | $0.0M | Form 4 |
| May 18, 2026 | Mark BrosiusEVP & Chief Mfg and Supply Cha | Sold plan | 18 | $422.47 | $0.0M | Form 4 |
| May 11, 2026 | Gary LoebEVP & Chief Legal and Complian | Sold plan | 400 | $446.95 | $0.2M | Form 4 |
| Apr 29, 2026 | Amy L LaddDirector | Sold plan | 119 | $463.50 | $0.1M | Form 4 |
| Apr 28, 2026 | Amy L LaddDirector | Sold plan | 500 | $473.46 | $0.2M | Form 4 |
| Mar 10, 2026 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 105 | $493.95 | $0.1M | Form 4 |
| Mar 9, 2026 | Mark BrosiusSVP & Chief Mfg and Supply Cha | Sold plan | 645 | $485.01 | $0.3M | Form 4 |
| Mar 6, 2026 | Mark BrosiusSVP & Chief Mfg and Supply Cha | Sold plan | 648 | $490.19 | $0.3M | Form 4 |
| Mar 5, 2026 | Mark BrosiusSVP & Chief Mfg and Supply Cha | Sold plan | 648 | $495.20 | $0.3M | Form 4 |
| Mar 4, 2026 | Mark BrosiusSVP & Chief Mfg and Supply Cha | Sold plan | 2,362 | $498.68 | $1.2M | Form 4 |
| Mar 3, 2026 | Mark BrosiusSVP & Chief Mfg and Supply Cha | Sold plan | 648 | $488.10 | $0.3M | Form 4 |
| Mar 3, 2026 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 4,728 | $487.18 | $2.3M | Form 4 |
| Mar 3, 2026 | Fredrik WidmanVP Corporate Controller | Sold plan | 118 | $487.18 | $0.1M | Form 4 |
| Mar 2, 2026 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 125 | $492.59 | $0.1M | Form 4 |
| Feb 27, 2026 | Patricia L WadorsSVP Chief Human Resources Offi | Sold plan | 220 | $499.71 | $0.1M | Form 4 |
| Feb 27, 2026 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 2,345 | $499.71 | $1.2M | Form 4 |
| Feb 27, 2026 | Fredrik WidmanVP Corporate Controller | Sold plan | 249 | $499.71 | $0.1M | Form 4 |
| Feb 11, 2026 | Fredrik WidmanVP Corporate Controller | Sold plan | 133 | $494.96 | $0.1M | Form 4 |
| Feb 11, 2026 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 421 | $494.96 | $0.2M | Form 4 |
| Feb 10, 2026 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 105 | $494.65 | $0.1M | Form 4 |
| Jan 29, 2026 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 126 | $520.02 | $0.1M | Form 4 |
| Jan 27, 2026 | Gary S GuthartDirector | Sold plan | 27,300 | $530.25 | $14.5M | Form 4 |
| Jan 27, 2026 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 230 | $532.61 | $0.1M | Form 4 |
| Dec 15, 2025 | Mark BrosiusSVP & Chief Mfg and Supply Cha | Sold plan | 464 | $548.49 | $0.3M | Form 4 |
| Dec 15, 2025 | Mark BrosiusSee Remarks | Sold plan | 464 | $548.49 | $0.3M | Form 4 |
| Dec 12, 2025 | Mark BrosiusSVP & Chief Mfg and Supply Cha | Sold plan | 4,500 | $547.36 | $2.5M | Form 4 |
| Dec 10, 2025 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 104 | $559.90 | $0.1M | Form 4 |
| Dec 1, 2025 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 125 | $568.99 | $0.1M | Form 4 |
| Dec 1, 2025 | Gary S GuthartExecutive Chair of the Board o, Director | Sold plan | 22,806 | $570.89 | $13.0M | Form 4 |
| Nov 12, 2025 | Craig H BarrattDirector | Sold plan | 750 | $580.00 | $0.4M | Form 4 |
| Nov 12, 2025 | Henry L CharltonEVP & Chief Commercial and Mkt | Sold plan | 13,731 | $580.00 | $8.0M | Form 4 |
| Nov 10, 2025 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 105 | $560.00 | $0.1M | Form 4 |
| Nov 10, 2025 | Brian Edward MillerEVP & Chief Digital Officer | Sold plan | 3,500 | $575.00 | $2.0M | Form 4 |
| Nov 5, 2025 | Fredrik WidmanVP Corporate Controller | Sold plan | 2,067 | $550.00 | $1.1M | Form 4 |
| Oct 29, 2025 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 125 | $543.00 | $0.1M | Form 4 |
| Oct 28, 2025 | Myriam CuretEVP & Chief Medical Officer | Sold plan | 7,562 | $548.43 | $4.1M | Form 4 |
| Oct 24, 2025 | Craig H BarrattDirector | Sold plan | 2,193 | $548.01 | $1.2M | Form 4 |
| Oct 24, 2025 | David J. RosaChief Executive Officer (CEO), Director | Sold plan | 24,500 | $547.55 | $13.4M | Form 4 |
| Oct 24, 2025 | Gary S GuthartExecutive Chair of the Board o, Director | Sold plan | 31,600 | $547.45 | $17.3M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Intuitive Surgical has $5.9B more cash than debt.
Cash, debt and the ratios that show how comfortably Intuitive Surgical can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.2B | $4.1B | $5.2B | $4.0B | $5.9B |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net debt / EBITDA | β2.0x | β2.1x | β2.4x | β1.4x | β1.7x |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Current ratio | 5.1x | 4.4x | 4.8x | 4.1x | 4.9x |
| Quick ratio | 4.6x | 3.8x | 4.0x | 3.2x | 4.0x |
| Total assets | $13.6B | $13.0B | $15.4B | $18.7B | $20.5B |
| Total liabilities | $1.6B | $1.9B | $2.0B | $2.2B | $2.5B |
| Shareholders' equity | $11.9B | $11.0B | $13.3B | $16.4B | $17.8B |
| Net debt (β = net cash) | β$4.2B | β$4.1B | β$5.2B | β$4.0B | β$5.9B |
KIRA Β· Its return on capital was 20.9%: every 100 invested in the business earned about 21 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Intuitive Surgical passes 5 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 7 / 9 | 5 / 9 | 5 / 9 |
| Accruals ratio | β0.1% | β0.5% | β0.9% |
| Altman Z'' | 11.30 | 11.74 | 12.06 |
What does the share cost, and how does it compare?
KIRA Β· At $451.63 a share, the company is worth $158.8B: 54.7 times its earnings of the last four quarters.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
β
Adds net cash of $5.9B and divides by 362.7M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
β
Reference multiples: today 54.8x Β· peers 28.4x Β· sector 27.9x.
KIRA Β· Intuitive Surgical grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 3 of 3.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Intuitive Surgical ISRG | $158.8B | 20.5% | 29.3% | 24.8% | 20.9% | 54.7x | 5 | |
| Baxter International BAX | $13.1B | 5.7% | β2.7% | 3.0% | β1.4% | β | 5 | Compare β |
| Zimmer Biomet ZBH | $18.8B | 7.2% | 13.3% | 17.9% | 4.9% | 23.7x | 6 | Compare β |
| Edwards Lifesciences EW | $52.3B | 11.6% | 20.8% | 22.0% | 15.7% | 52.0x | 5 | Compare β |
| Steris STE | $22.5B | 8.7% | 18.6% | 16.4% | 9.6% | 28.1x | 9 | Compare β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.7B | $3.1B | $3.7B | $4.5B | $4.4B | $5.7B | $6.2B | $7.1B | $8.4B | $10.1B |
| Gross profit | $1.9B | $2.2B | $2.6B | $3.1B | $2.9B | $4.0B | $4.2B | $4.7B | $5.6B | $6.6B |
| Research and development | $240M | $329M | $418M | $557M | $595M | $671M | $879M | $999M | $1.1B | $1.3B |
| Operating income | $950M | $1.1B | $1.2B | $1.4B | $1.0B | $1.8B | $1.6B | $1.8B | $2.3B | $2.9B |
| Pretax income | $985M | $1.1B | $1.3B | $1.5B | $1.2B | $1.9B | $1.6B | $2.0B | $2.7B | $3.3B |
| Income tax | $247M | $434M | $155M | $120M | $140M | $162M | $262M | $142M | $336M | $435M |
| Net income | $738M | $671M | $1.1B | $1.4B | $1.1B | $1.7B | $1.3B | $1.8B | $2.3B | $2.9B |
| Diluted EPS | $2.09 | $1.92 | $3.16 | $3.85 | $2.94 | $4.66 | $3.65 | $5.03 | $6.42 | $7.87 |
| Diluted shares | 0.35B | 0.35B | 0.36B | 0.36B | 0.36B | 0.37B | 0.36B | 0.36B | 0.36B | 0.36B |
| Cash flow | ||||||||||
| Cash from operations | $1.1B | $1.1B | $1.2B | $1.6B | $1.5B | $2.1B | $1.5B | $1.8B | $2.4B | $3.0B |
| Capital expenditure | $53.9M | $191M | $187M | $426M | $342M | $340M | $532M | $1.1B | $1.1B | $540M |
| Free cash flow | $1.0B | $953M | $982M | $1.2B | $1.1B | $1.7B | $958M | $750M | $1.3B | $2.5B |
| Depreciation and amortization | $88.9M | $95.0M | $120M | $200M | $271M | $307M | $354M | $402M | $456M | $613M |
| Stock-based compensation | $178M | $209M | $261M | $336M | $395M | $449M | $513M | $593M | $677M | $788M |
| Acquisitions | $0.0M | $0.0M | $87.9M | $59.7M | $37.7M | $22.7M | $12.8M | $8.9M | $1.0M | $13.9M |
| Share buybacks | $42.5M | $2.3B | $0.0M | $270M | $134M | $0.0M | $2.6B | $416M | $0.0M | $2.3B |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $42.5M | $2.3B | $0.0M | $270M | $134M | $0.0M | $2.6B | $416M | $0.0M | $2.3B |
| Balance sheet | ||||||||||
| Cash and short-term investments | $2.6B | $2.0B | $3.1B | $3.2B | $5.1B | $4.2B | $4.1B | $5.2B | $4.0B | $5.9B |
| Total debt | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $3.3B | $2.8B | $4.3B | $4.7B | $6.6B | $5.8B | $6.3B | $7.9B | $7.1B | $9.8B |
| Current liabilities | $597M | $663M | $821M | $1.0B | $965M | $1.1B | $1.4B | $1.7B | $1.7B | $2.0B |
| Inventory | $182M | $241M | $409M | $596M | $602M | $587M | $893M | $1.2B | $1.5B | $1.8B |
| Property and equipment, net | $458M | $613M | $812M | $1.3B | $1.6B | $1.9B | $2.4B | $3.5B | $4.6B | $5.3B |
| Total assets | $6.5B | $5.8B | $7.8B | $9.7B | $11.2B | $13.6B | $13.0B | $15.4B | $18.7B | $20.5B |
| Total liabilities | $709M | $996M | $1.2B | $1.4B | $1.4B | $1.6B | $1.9B | $2.0B | $2.2B | $2.5B |
| Shareholders' equity | $5.8B | $4.8B | $6.7B | $8.3B | $9.7B | $11.9B | $11.0B | $13.3B | $16.4B | $17.8B |
| Margins | ||||||||||
| Gross margin | 69.9% | 70.2% | 69.9% | 69.5% | 65.7% | 69.3% | 67.4% | 66.4% | 67.5% | 66.0% |
| Operating margin | 35.1% | 33.9% | 32.2% | 30.7% | 24.1% | 31.9% | 25.4% | 24.8% | 28.1% | 29.3% |
| EBITDA margin | 38.4% | 36.9% | 35.4% | 35.2% | 30.3% | 37.3% | 31.0% | 30.5% | 33.6% | 35.4% |
| Net margin | 27.3% | 21.4% | 30.3% | 30.8% | 24.3% | 29.9% | 21.3% | 25.2% | 27.8% | 28.4% |
| FCF margin | 38.2% | 30.4% | 26.4% | 26.2% | 26.2% | 30.7% | 15.4% | 10.5% | 15.6% | 24.8% |
| Returns | ||||||||||
| Return on capital | 23.6% | 21.2% | 32.7% | 29.1% | 19.1% | 26.9% | 17.9% | 21.6% | 19.9% | 20.9% |
| Return on capital employed | 18.4% | 19.3% | 19.8% | 17.5% | 11.1% | 16.1% | 13.2% | 14.0% | 15.3% | 16.6% |
| Return on equity | 14.6% | 12.7% | 19.7% | 18.5% | 11.8% | 15.8% | 11.5% | 14.8% | 15.6% | 16.7% |
| Return on assets | 13.0% | 10.9% | 16.6% | 15.7% | 10.2% | 13.8% | 10.0% | 12.7% | 13.6% | 14.6% |
| Growth | ||||||||||
| Revenue growth | 13.5% | 16.0% | 18.7% | 20.3% | β2.7% | 31.0% | 9.0% | 14.5% | 17.2% | 20.5% |
| Net income growth | 25.4% | β9.1% | 68.1% | 22.3% | β23.1% | 60.7% | β22.4% | 36.0% | 29.2% | 23.0% |
| EPS growth | 20.9% | β7.8% | 64.5% | 21.7% | β23.6% | 58.5% | β21.7% | 37.8% | 27.6% | 22.6% |
| FCF growth | 42.5% | β7.7% | 3.0% | 19.4% | β2.5% | 53.1% | β45.2% | β21.8% | 73.9% | 91.0% |
| Share count change | 3.7% | β1.4% | 2.2% | 0.6% | 0.7% | 1.3% | β1.0% | β1.3% | 1.3% | 0.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | β2.5x | β1.7x | β2.3x | β2.1x | β3.9x | β2.0x | β2.1x | β2.4x | β1.4x | β1.7x |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Current ratio | 5.5x | 4.2x | 5.3x | 4.5x | 6.9x | 5.1x | 4.4x | 4.8x | 4.1x | 4.9x |
| Quick ratio | 5.1x | 3.9x | 4.8x | 4.0x | 6.2x | 4.6x | 3.8x | 4.0x | 3.2x | 4.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.0% | 6.1% | 5.0% | 9.5% | 7.8% | 6.0% | 8.6% | 14.9% | 13.3% | 5.4% |
| Stock comp / revenue | 6.6% | 6.7% | 7.0% | 7.5% | 9.1% | 7.9% | 8.3% | 8.3% | 8.1% | 7.8% |
| Payouts / FCF | 4.1% | 238.6% | 0.0% | 23.0% | 11.8% | 0.0% | 272.1% | 55.5% | 0.0% | 92.2% |
| Quality scores | ||||||||||
| Piotroski F-score | 6.0 | 5.0 | 6.0 | 3.0 | 4.0 | 6.0 | 4.0 | 7.0 | 5.0 | 5.0 |
| Altman Z'' | 13.1 | 8.8 | 10.7 | 10.2 | 12.2 | 12.2 | 10.4 | 11.3 | 11.7 | 12.1 |
| Accruals ratio | β6.1% | β7.7% | β0.6% | β2.5% | β4.1% | β3.1% | β1.3% | β0.1% | β0.5% | β0.9% |
Source: SEC EDGAR XBRL filings (CIK 0001035267). Data updated October 21, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
